Tempest Therapeutics Inc is a biotechnology company focused on developing innovative therapies for cancer treatment
The company is dedicated to advancing a portfolio of novel drug candidates that target various cancer types through both immunotherapy and small molecule approaches. Tempest Therapeutics aims to harness the body’s immune system and other biological mechanisms to combat tumors effectively, enhancing patient outcomes in oncology care. Through cutting-edge research and collaboration, the company seeks to address significant unmet medical needs in the fight against cancer.
Tempest Therapeutics enters a Phase 3 trial for its liver cancer drug amezalpat, in collaboration with Roche. The trial follows positive data from a Phase 2 study showing improved survival in patients with unresectable hepatocellular carcinoma.
Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin in Q1 2025.
Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients using TPST-1120 combined with atezolizumab and bevacizumab.
Shares of Byrna Technologies Inc. (NASDAQBYRN) rose sharply during Friday’s session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition.
